ERBB3 and neoplasm: EGFR targeting with CAR-T causes gastrointestinal, respiratory, and hematological toxicity. New strategies that target local adjacent tumor tissue antigens like FAP, HER3, and NKGD2 are in phase I and II clinical trials to assess safety [138].